Key Insights Significant control over IO Biotech by private equity firms implies that the general public has more ...

Following a surge of 52.47% during regular trading session on Tuesday, Polyrizon Ltd (NASDAQ: PLRZ) witnessed a dip of 12.02% ...

Lumos Diagnostics signs exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of FebriDX in US.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

Their first product, Illuccix, is a diagnostic imaging agent that allows PET scanners to light up the prostate cancer cells ...

Liquidia stock earns the No. 246 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG Therapeutics TGTX and Inhibrx Biosciences INBX are among the top 5 highly rated ...

Five acquisitions in 2025—including Cargo and Allakos—have put Concentra Biosciences in the spotlight. Learn what’s behind ...

Shares of Mink Therapeutics Inc. (NASDAQ:INKT) dropped 21% following the company’s announcement of a potential $50 million at ...

Integrated aquaculture group, Camaroe Bhd, has received approval from Bursa Malaysia Securities Bhd to list on the ACE Market of the stock exchange.

Polyrizon Ltd. (Nasdaq: PLRZ) (the 'Company” or 'Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ('Gain”, or the 'Company”), a clinical-stage biotechnology company leading the ...